ALBI_albumin_bilirubin_score v.1
The ALBI (Albumin-Bilirubin) grade is a simple, evidence-based, objective, and discriminatory method of assessing liver function/dysfunction that independently influence survival in Hepatocellular carcinoma (HCC) patients.
To provide assessment and interpretation of ALBI score for predicting survival in HCC patients.
For patients with HCC of all stages. The ALBI score is calculated based on the formula: ALBI = (log bilirubin × 0.66) + (albumin × -0.085). The bilirubin is in μmol/L and albumin in g/L. Grade 1 is defined as ALBI score of ≤-2.60 with the median survival of 18.5-85.6 months. Grade 2 is defined as ALBI score of >-2.60 to ≤-1.39 with the median survival of 5.3-46.5 months. Grade 3 is defined as ALBI score of >-1.39 with the median survival of 2.3-15.5 months.
1. Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550-8. 2. Hiraoka A, Michitaka K, Kumada T, et al. Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer. 2017;6(4):325-336. 3. Chen B, Lin S. Albumin-bilirubin (ALBI) score at admission predicts possible outcomes in patients with acute-on-chronic liver failure. Medicine (Baltimore). 2017;96(24):e7142. 4. Lee PC, Chen YT, Chao Y, et al. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma. Liver Int. 2018;38(2):321-330.
OBSERVATION.lab_test-liver_function.v1, OBSERVATION.albi_score.v0, EVALUATION.albi_score.v0
